Roche is to merge with and fully acquire oral therapeutics developer Anadys Pharmaceuticals in a $230 million cash deal.
The acquisition follows Roche’s plans to expand future treatment options for patients with hepatitis C virus (HCV) infection.
Jean-Jacques Garaud, Global Head of Roche Pharma Research and Early Development, said: “Our aim is to offer physicians and hepatitis patients a powerful combination of therapies that bring us closer to a cure.”
San Diego-based Anadys’ most advanced drug candidate, Setrobuvir (ANA598), is a direct-acting antiviral (DAA) inhibitor, which is currently being evaluated in a Phase II study in combination with Roche’s Pegasys (pegylated interferon) and Copegus (ribavirin).
Roche plans to explore Setrobuvir’s use in combination with other DAAs already within its portfolio, with and without interferon.
Steve Worland, President and CEO of Anadys, said: “With Roche’s considerable capabilities and experience in HCV, this acquisition provides the best chance of success for the new potential treatments our team has been dedicated to developing.”
In addition to its lead programme with ANA598, Anadys is developing ANA773, an oral, small-molecule inducer of innate immunity that may prove useful for treating HCV as well as other chronic infections and cancer.
Headquartered in Basel, Switzerland, Roche provides research-focused healthcare with strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotechnology company with focus in oncology, virology, inflammation, metabolism and CNS medicines.